The AML1 and CBF␤ subunits of core binding factor (CBF) are involved in several chromosomal abnormalities frequently associated with acute leukemias. As a result, the CBF␤-SMMHC, AML1-ETO and AML1-MDS1/EVI1 fusion proteins are expressed in subsets of acute myeloid leukemia, and TEL-AML1 is expressed in B-lineage acute lymphocytic leukemia. These CBF oncoproteins likely contribute to leukemogenesis in part by inhibiting endogenous CBF. As a result they are expected to inhibit differentiation and perhaps apoptosis. In addition, the domains unique to each fusion protein may also contribute to leukemogenesis via unique mechanisms.
Introduction
Acute human leukemias commonly harbor chromosomal translocations. Many of these translocations lead to the abberant expression of transcription factors, either as a result of over-expression or as part of novel fusion proteins. The subject of this review is a group of such fusion proteins which include segments derived from core binding factor (CBF), a key regulator of early hematopoiesis. Although their participation in leukemogenesis has not been established, these novel proteins are referred to here as the 'CBF oncoproteins'. In this review, attention will be drawn to the effects of CBF oncoproteins on molecular pathways regulating cell proliferation, differentiation and survival, to provide insight into how they might contribute to leukemogenesis. As the CBF oncoproteins impact on the activity of endogenous CBF, it is appropriate to begin with an overview of this family of transcriptional regulators.
Core binding factors
CBF was first purified based on its ability to interact with the enhancer core sites of polyomavirus or Moloney murine leukemia virus and is also known as polyoma enhancer binding protein 2 (PEBP2). 1, 2 CBF is in fact a family of heterodimeric transcription factors containing a common CBF␤ subunit and one of three CBF␣ subunits. [3] [4] [5] [6] [7] CBF␣1 is also designated CBFA1, PEBP2␣A and AML3. CBF␣2 is equivalent to CBFA2, PEBP2␣B and AML1, and CBF␣3 is also termed CBFA3, PEB-P2␣C and AML2. CBF␤ is also designated CBFB and PEBP2␤. Several splice variants of the CBF␣ and CBF␤ subunits have been detected, including an AML1 variant lacking the DNA-Runt, the Drosophila CBF␣ subunit, acts as a repressor as well as an activator. 38, 39 Repression by Runt is mediated by interaction of a C-terminal motif, VWRPY, with Groucho. 40 Activation mediated by AML1 can be attenuated by interaction with the TLE, a mammalian homolog of Groucho. 41, 42 Ear-2, a member of the nuclear hormone receptor super-family, also inhibits AML1B trans-activation via direct interaction. 43 AML1 can interact with the mSin3 and N-CoR corepressors. 44 One of these mechanisms may account for repression of the p21 promoter by AML1. 44 AML1B can be phosphorylated on serines 276 and 293 by ERK and is phosphorylated in hematopoietic cells. [45] [46] [47] Mutation of these serines reduces AML1B trans-activation in p19 cells, but does not affect its cooperation with PU.1 or C/EBP␣ in CV-1 cells. 30, 47 The role of AML1 phosphorylation in hematopoietic cells remains to be determined. Amino acids 351-381 of AML1, and related segments of CBF␣1 and CBF␣3, mediate their strong interaction with the nuclear matrix; however, the role of the nuclear matrix in the regulating CBF activities is unknown. 48 CBF␤ is widely expressed, whereas AML1B is largely restricted to hematopoietic cells, including B-and T-lymphoid cells, granulocytic and monocytic cells, megakaryocytes, and CD34 + marrow cells. 7, 21, 46, 49, 50 CBF␣ subunits are also present in erythroid precursors during embryogenesis, but not in adult marrow. 51 During development AML1 is expressed predominantly in primitive hematopoietic stem cells and from endothelial cells present in regions where hematopoietic cells are developing, although expression in other lineages is also evident. 52, 53 Consistent with their expression in hematopoietic stem cells, mice lacking the genes encoding AML1 or CBF␤ die in utero due to lack of fetal hematopoiesis, including lymphopoiesis. [54] [55] [56] [57] [58] CBF␣ subunits are located in the nucleus. 59 The majority of CBF␤ is cytoplasmic, likely reflecting its affinity for the actin cytoskeleton and its expression in excess of CBF␣.
59,60
The CBF oncoproteins Chromosomal abnormalities involving subunits of CBF are common in acute leukemias. Inv(16)(p13;q22) or the less common t(16;16)(p13;q22) are present in 10% of acute myeloid leukemia (AML) and encode CBF␤-SMMHC, in which the majority of CBF␤ is fused to the tail domain of a smooth muscle myosin heavy chain (SMMHC). 61 Inv16 is associated with the FAB M4eo subset of AML, although about 15% of cases have another morphology, usually M2 or M5. t(8;21)(q22;q22) is present in 12% of AML, characteristically FAB M2, and encodes AML1-ETO, which includes the DNAbinding domain of AML1 and the majority of ETO. [62] [63] [64] [65] [66] t(3;21)(q26;q22) is an uncommon translocation associated with myelodysplastic syndrome, therapy-associated AML, or CML blast-crisis and encodes AML1-MDS1/EVI1. [67] [68] [69] Therapy-associated AMLs carrying translocations involving the AML1 locus and several novel loci, including one encoding an ETO homolog, were recently identified. 70, 71 And 25% of pediatric B-lineage acute lymphocytic leukemias (ALL) contain t(12;21)(p13;q22), which encodes TEL-AML1. 72, 73 These CBF oncoproteins are diagrammed in Figure 1 .
CBF␤-SMMHC
Several variants of CBF␤-SMMHC RNA and protein have been detected in AMLs harboring inv (16) . 61, [74] [75] [76] The most common variant includes 165 CBF␤ residues and 446 SMMHC residues and is detected as a 70 kDa protein on Western blotting. The CBF␤ segment retains the ability to bind CBF␣ subunits. 77 The SMMHC domain is ␣-helical and consists of multiple, related 28 amino acid regions. Each 28 amino acid region consists of four heptads in which the i and i+4 amino acid is often hydrophobic. As a result, one face of the ␣-helix is hydrophobic, allowing dimerization. The other face is hydrophilic, with alternating positively and negatively charged zones. This face of the myosin rod mediates multimerization, which occurs with a 98 amino acid (3.5 repeat) stagger. 78 In addition, SMMHC has a non-helical C-terminal tail. Human SMMHC has two isoforms, SMMHC204 and SMMHC200, which differ in the length of their non-helical C-termini as a result of alternative splicing. 79 CBF␤-SMMHC204 is more highly expressed than the CBF␤-SMMHC200 isoform in M4eo AMLs. 76 The non-helical tail is thought to enforce staggered multimerization, as non-staggered multimerization would result in steric hindrance from adjacent non-helical domains. 80 CBF␤-SMMHC can interfere with CBF DNA-binding by sequestering CBF␣ subunits in complexes formed as a result of multimerization via the SMMHC domain. 76, 81 In leukemic blasts, CBF␤-SMMHC was detected in small nuclear speckles, and at high concentration CBF␤-SMMHC forms rod-like structures in fibroblastic and hematopoietic cell lines. 76, 81, 82 The composition, architecture and biochemical interactions of these structures and their relevance to leukemogenesis is unknown. CBF␤-SMMHC sequesters CBF␣ subunits in the cytoplasm of adherant cell lines. 59, 83, 84 This may result from increased affinity of CBF␤-SMMHC for the cytoskeleton, compared with CBF␤, perhaps as a result of interaction of its SMMHC segment with cytoskeletal-associated non-muscle myosins. 85 CBF␤-SMMHC:CBF␣ complexes retain the ability to bind DNA. 77, 81 Therefore, CBF␤-SMMHC might also interfere with CBF␣ trans-activation via local effects on promoter/enhancer transcription complexes.
Via one or more of these mechanisms, CBF␤-SMMHC inter-
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feres with CBF trans-activation. 83, 86, 87 Deletion of 11 N-terminal CBF␤ residues, required for interaction with CBF␣ subunits, obviated the ability of CBF␤-SMMHC to interfere with CBF␣ DNA-binding and trans-activation. 86 Deletion of 283 Cterminal residues from the SMMHC segment, required for dimerization, also prevented CBF␤-SMMHC from interfering with CBF activities. 86 The phenotype of mice expressing CBF␤-SMMHC provides additional evidence that CBF␤-SMMHC interferes with the activities of endogenous CBF. A cDNA encoding the SMMHC domain was 'knocked-in' to the CBF␤ genomic locus at a position which results in expression of CBF␤-SMMHC. 88 These mice fail to develop definitive hematopoiesis, just as do mice lacking AML1 or CBF␤. CBF␤-SMMHC has also been expressed specifically in the myeloid lineage using the MRP8 promoter. 89 These mice did not develop leukemia and had only a mild defect in neutrophil maturation, perhaps because expression was not achieved at an early enough stage of hematopoiesis.
Inhibition of cell cycle progression may account for the lack of hematopoiesis in mice lacking CBF activity in marrow cells. 81 Induction of CBF␤-SMMHC from the metallothionein promoter in 32D c13 myeloid or in Ba/F3 lymphoid cells led to decreased endogenous CBF DNA-binding and to slowed proliferation, with an inhibition of the G1 to S transition. Apoptosis was not induced. An increase in hypophosphorylated Rb was detected, indicating that the block in G1 progression was at or preceeding the restriction point. Inhibition of proliferation was dependent on the ability of CBF␤-SMMHC to bind CBF␣ subunits and on its ability to multimerize. 86 The SMMHC domain alone did not inhibit cell growth, even when directed to the nucleus with an SV40 nuclear localization signal. Two additional lines of evidence indicate that CBF regulates the G1 to S transition. First, over-expression of AML1 in 32D c13 cells accelerates G1 progression. 90 Second, inhibition of AML1 activities with a fusion protein containing the AML1 DNA-binding domain and a KRAB repression domain strongly inhibits G1 progression. 91 But if CBF␤-SMMHC inhibits cell cycle progression, how does it contribute to transformation? As will be elaborated on below, additional genetic mutations may by-pass the growth inhibitory effects of CBF␤-SMMHC, potentiating its ability to contribute to leukemogenesis. Consistent with this model, chimeric CBF␤-SMMHC knock-in mice exposed to the mutagen ethylnitrosourea develop acute myeloid leukemias within 4 months. 92 Yet to be identified second genetic 'hits' might allow CBF␤-SMMHC to inhibit myeloid differentiation, as several myeloid-specific genes are regulated by CBF. Inhibition of CBF activities by KRAB-AML1 strongly inhibits MPO mRNA expression in 32D cl3 cells. 91 In addition to inhibiting differentiation, CBF␤-SMMHC might contribute to leukemogenesis by inhibiting apoptosis. Ba/F3 cells expressing CBF␤-SMMHC have attenuated p53 induction and prolonged survival after exposure to ionizing radiation or etoposide. 93 Also, it is possible that the SMMHC domain contributes to transformation via its interactions with endogenous non-muscle myosins. Actin filament morphology was altered when CBF␤-SMMHC was expressed in fibroblastic cell lines. 85 Perhaps similar alterations would interfere with adhesion and stimulate proliferation in hematopoietic progenitors.
AML1-ETO
AML1-ETO has been detected as a 94 kDa protein in leukemic blasts and is located predominantly in the nucleus of leukemic cells. 46, [94] [95] [96] In addition to AML1-ETO, t(8;21) encodes transcripts spliced out-of-frame to ETO and predicted to express the AML1 Runt domain linked to 4-7 additional residues. 97 However, a protein of this size is not detected in leukemic cells, and high-level expression of the AML1 Runt domain had no effect on 32D cl3 cell proliferation or granulocytic differentiation.
98 AML1-ETO retains the ability to heterodimerize with CBF␤ and interact with CBF DNA-binding sites. Once bound to DNA, AML1-ETO potently inhibits transcription. 23, 87, 99, 100 Inhibition of transcription is potentiated by interaction of the ETO domain with the N-CoR and/or mSin3 corepressors. [101] [102] [103] Transcriptional inhibition by AML1-ETO is also enhanced by its interaction with MTGR1, a protein homologous to ETO expressed in myeloid cells.
104 AML1-ETO apparently has a competitive advantage over AML1B for heterodimerization with CBF␤ and so DNA-binding, and as a result low levels of AML1-ETO can dominate AML1B. 96, 99 AML1-ETO 'knock-in' mice lack fetal hematopoiesis, as do AML1-or CBF␤-null mice, indicating that AML1-ETO inhibits AML1 activities in vivo. 105, 106 AML1-ETO also activates the promoters of the genes encoding bcl-2 and the M-CSF receptor via AML1-binding sites, and the UBP43 ubiquitin protease is over-expressed in the yolk sac of AML1-ETO mice. [107] [108] [109] The relevance of transactivation of these or other genes for leukemogenesis by AML1-ETO is unknown. However, retention of macrophage colony-forming units by one AML1-ETO murine line and increased proliferative potential of hematopoietic progenitors from another suggests that AML1-ETO does more than just inhibit CBF activities. 105, 106 Activation of genes containing AML1-binding sites and/or protein-protein interactions mediated by the AML1 or ETO domains might be relevant to these cellular phenotypes and to leukemogenesis by AML1-ETO.
AML1-ETO retains 574 residues of the 604 amino acid ETO. ETO has several domains homologous to the Drosophila Nervy protein and is predominantly expressed in neurons. 65, 110 ETO RNA or protein has also been detected in hematopoietic cell lines and in CD34 + marrow cells. 46, 111, 112 ETO has been detected in the nucleus of leukemic cells and in the nucleus and cytoplasm of neurons. 46, 113 The four regions of ETO homologous to Nervy are designated NHR1-4. NHR1 is highly homologous to a segment of the Drosophila TAF110 co-activator. The amino acid sequence of NHR2 predicts that it will form an ␣-helical domain containing a hydrophobic face. Heterodimerization of ETO or AML1-ETO with MTGR1 is mediated by NHR2, perhaps via hydrophobic interactions.
104 NHR4 contains two zinc-finger motifs and is also termed the MYND domain. The zinc-fingers of the MYND domain interact with the N-CoR co-repressor.
102,103 N-CoR can also interact with ETO via NHR2, and the mSin3 corepressor can interact with ETO even if NHR2, 3 and 4 are deleted. 102 Both NHR2 and NHR4 are required for optimal trans-repression of the MDR-1 or NP-3 promoters, with NHR4 making the largest contribution. 100, 102 On the other hand, NHR4 did not contribute to trans-repression of the TCR␤ promoter.
14, 104 The importance of interactions mediated by the ETO domain for leukemogenesis is suggested by the finding that rare cases of AML harboring t(16;21) express AML1-MTG16. MTG16 is homologous to ETO and to MTGR1 and contains NHR1-4. 71 A fourth member of the ETO family, ETO-2, was recently identified as well. 114 AML1-ETO inhibits the terminal granulocytic differentiation of the 32D cl3 and L-G myeloid cell lines, the monocytic differentiation of U937 cells, and the erythroid differentiation of K562 and TF-1 cells. 43, 87, 95, 103, 104, 115 The stage at which differentiation is inhibited by AML1-ETO in myeloid lines remains to be determined, as their expression of early markers of granulopoiesis, such as MPO, has not been reported. Inhibition of L-G myeloid cell differentiation was not affected by deletion of NHR3 and NHR4, but was prevented by deletion of NHR2. 104 Consistent with these results, inhibition of AML1-ETO expression in Kasumi-1 cells increased their differentiation. 116 As exogenous bcl-2 does not prevent 32D cl3 differentiation, activation of the bcl-2 gene alone does not account for inhibition of differentiation by AML-ETO. 117, 118 The AML1 Runt domain in AML1-ETO interacts with C/EBP␣.
30,87 C/EBP␣ directly induces both granulocytic differentiation and cell cycle arrest in 32D cl3 myeloid cells. 119 Perhaps AML1-ETO inhibits myeloid differentiation and stimulates proliferation by disrupting C/EBP␣ trans-activation or by interfering with C/EBP␣:p107 interactions. 120 Several investigators have found that AML1-ETO has a proliferative effect. AML1-ETO was introduced into murine marrow cells using a retroviral vector. Although AML1-ETO reduced the total number of colonies obtained, only those colonies transduced with AML1-ETO could be replated over multiple generations and expanded into blastic cell lines. 106 Fetal liver cells derived from one of the two reported murine lines expressing AML1-ETO from the AML1 locus contain multipotential hematopoietic progenitors with a high replating efficiency. 105, 106 There is presently no explanation for the fact that only one of the two laboratories which generated AML1-ETO 'knock-in' mice observed this phenomenon. Also, the abnormal progenitors observed are not fully transformed, indicating that additional genetic events are required for leukemogenesis.
In one study, AML1-ETO, but not AML1B or ETO, transformed two sources of NIH3T3 cells. 121 Transformation did not occur if the AML1B Runt domain or the ETO NHR2 domain were deleted, but was not dependent upon the presence of NHR4. In other studies, ETO and AML1B contributed to transformation of NIH 3T3 cells, reflecting the heterogeneity of this cell line. [122] [123] [124] The relevance of results obtained with fibroblastic lines to leukemogenesis by CBF oncoproteins is debatable, as CBF is not expected to be active in them. Perhaps AML1-ETO transforms 3T3 cells be interacting with CBF-binding sites within genes normally activated or repressed by CBF in hematopoietic cells.
Development of t(8;21) and expression of AML1-ETO may be an early event in leukemogenesis. Consistent with this order of events, several investigators have detected AML1-ETO transcripts by PCR in patients in long-term remission.
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AML1-MDS1/EVI1
t(3;21) is an uncommon translocation which occurs most often in therapy-related myelodysplastic syndrome (MDS) or AML and in chronic myeloid leukemia in blast crisis. As a result of t(3;21), the first six exons of the AML1 gene, encoding the Runt domain, are positioned upstream of three tandem encoding EAP, MDS1 and EVI1. Transcripts encoding AML1-MDS1, the AML1 runt domain, and AML1-MDS1/EVI1 have been detected in marrow cells from these patients. [67] [68] [69] 129 These different transcripts arise as a result of alternative splicing.
EAP is ribosomal L22. AML1-EAP is an out-of-frame fusion which results in expression of the AML1 Runt domain linked to 17 non-EAP residues. 67 MDS1 exists both as a short, unique transcript and as a fusion transcript with EVI1 in normal cells. 130 In the MDS1/EVI1 fusion, EVI1 is extended at its Nterminus by 188 codons, including a portion of MDS1 and a segment that is non-coding in the EVI1 transcript. EVI1 also exists as a unique transcript in normal cells. 131 The functions of the MDS1, EVI1 and MDS1/EVI1 proteins are not known. MDS1/EVI1 is a 145 kDa nuclear protein normally expressed in the kidney and ovary. 132 Low levels of MDS1/EVI1 and/or EVI1 RNA have been detected in primitive myeloid cells. 131, 133 MDS1/EVI1 and EVI1 contain clusters of seven and three zinc fingers. The consensus binding site for fingers 1-7 has a GACAAGATA core, which includes a potential binding site for GATA family transcription factors. [134] [135] [136] The second set of fingers binds GAAGATGAG. 137 EVI1 inteferes with GATA-1-mediated transactivation and acts as a transcriptional repressor in other contexts as well. 131, 133, 138, 139 In contrast, MDS1/EVI1 activates transcription via the AGATA motif. A PR domain spanning the MDS1/EVI1 junction is required for MDS1/EVI1-mediated trans-activation. 131 Also, EVI1 indirectly activates transcription of the c-fos promoter, an effect which could contribute to leukemogenesis, although induction of cfos in hematopoietic cells has not been demonstrated. 140 Mice lacking MDS1/EVI1 and EVI1 die as embryos with defects in cardiac, somite and peripheral nerve development. 141 The EVI1 gene, located at 3q26, is involved in t(3;3)(q21;q26) and inv(3)(q21;q26) in 1-2% of AML. EVI1, without the N-terminal MDS1 segment, is over-expressed in these leukemias. EVI1 and/or MDS1/EVI1 are also overexpressed in 30% of patients with myelodysplastic syndrome without an associated 3q26 abnormality. [142] [143] [144] [145] High-level, but not low-level, expression of EVI1 in 32D cl3 cells blocks G-CSF signalling, resulting in lack of differentiation and cell death upon transfer to G-CSF. 146, 147 AML1-MDS1/EVI1 and AML1/MDS1 can interfere with AML1B-mediated transactivation.
148,149 32D cl3 cells expressing AML1-MDS1/EVI1 undergo cell death without differentiation, mimicking the effect of EVI1 alone. 148 Also, AML1-MDS1/EVI1 and EVI1 prevent TGF␤-mediated growth inhibition of 32D cl3 cells and other cell types. [150] [151] [152] This effect depends on the integrity of the first zinc finger cluster and of a repression domain located between the zinc finger clusters. 150, 152 Interference with TGF␤-mediated growth inhibition can be accounted for by interaction of AML1-MDS1/EVI1 or EVI1 with Smad3, a downstream effector of TGF␤ signalling. [150] [151] [152] Thus, both inhibition of CBF activities and independent effects of the MDS1/EVI1 domain might contribute to leukemogenesis by AML1-MDS1/EVI1.
TEL-AML1
t(12;21) is present in 25% of pediatric and 3% of adult Blineage ALL [153] [154] [155] and encodes TEL-AML1. TEL, like one-third of Ets family transcription factors, contains an N-terminal pointed (PNT) domain, which mediates dimerization, and a Cterminal DNA-binding domain homologous to Ets-1 and other factors. 156 In TEL-AML1 the majority of TEL, save its DNAbinding domain, is fused N-terminal to the majority of AML1B. 72, 73 TEL-AML1 interacts with AML1-binding sites and represses activation of the TCR␤ and IL-3 promoters by AML1. 157, 158 This trans-repression was dependent upon the integrity of the PNT domain of TEL, the Runt domain of AML1, and AML1 amino acids 216-290. Little information has been reported on the biologic consequences of TEL-AML1 expression in hematopoietic cells. In Ba/F3 lines TEL-AML1 binds endogenous TEL and slows proliferation, perhaps due to reduced CBF and/or TEL activities (F Bernardin, O Bernard and ADF, unpublished).
The majority of B-lineage ALLs carrying t(12;21) also have the other copy of TEL deleted, 15/16 in one study 159 and 4/6 in another. 160 Loss of the second TEL allele is occasionally seen for the first time at relapse in ALLs carrying t(12;21), indicating that loss of both copies of TEL may not be required initially for transformation. 159, 160 In addition, a small number of B-lineage ALLs have both copies of TEL deleted, indicating that loss of TEL can contribute to transformation even in the absence of TEL-AML1. 161, 162 One hypothesis that has been advanced for the role of TEL deletions is that the normal TEL allele interferes with the activities of TEL-AML1 by interaction via their shared PNT domains. Consistent with this model, several ALLs carrying small deletions in the TEL locus delete the exons encoding the PNT domain. 161 An alternative hypothesis, elaborated upon below, is that loss of TEL itself provides cells with a proliferative advantage.
Exogenously expressed TEL can bind 5Ј-ATAAACAG-GAAGTGG-3Ј, which contains a GGAA core often present in Ets-binding sites. 163 DNA-binding by endogenous TEL has not been reported. The TEL PNT domain is capable of mediating homodimerization. 164, 165 TEL also heterodimerizes with Fli-1, another Ets factor, and interferes with trans-activation of the GPIX promoter by Fli-1. 166 TEL-AML1 was less effective than TEL in inhibiting Fli-1 activity. TEL is widely expressed, and mice lacking TEL die during embryogenesis. 167 These mice die in utero with defects in multiple cell types. Yolk sac hematopoiesis is normal, but fetal and adult hematopoiesis and lymphopoiesis could not be assessed. Analysis of chimeric mice, however, shows that TEL(−/−) cells do not contribute to bone marrow hematopoiesis, although they contribute normally to yolk sac and fetal liver myeloid and erythroid progenitors. Also, fully differentiated B and T cells are detected in the spleen and thymus of adult TEL(−/−)/RAG-2(−/−) chimeras, albeit at reduced numbers. 168 The authors conclude that the TEL gene product is required for hematopoietic cells to home to the bone marrow but not for their differentiation. They suggest that the same intracellular defect which interferes with marrow homing and/or adhesion of TEL(−/−) cells might also provide ALL blasts with a proliferative advantage. And transformation by TEL-AML1 may depend in part upon its binding to and inhibiting TEL activities, as proposed. 168, 169 I favor the hypothesis that loss of TEL contributes to leukemogenesis by potentiating the ability of TEL-AML1 to repress CBF-regulated genes, but experiments involving expression of TEL-AML1 with or without TEL, and perhaps with additional genetic alterations, will be required to settle this issue.
Leukemogenesis by CBF oncoproteins
As discussed above, each CBF oncoprotein may contribute to leukemogenesis via effects on endogenous CBF and via unique contributions of the domains fused to AML1 or CBF␤ (Figure 2) . Each of the CBF oncoproteins can inhibit CBF activities. The relevance of CBF inhibition for leukemogenesis is supported by the finding that four of 90 AMLs lacking t(8;21) or inv(16) carry missense or nonsense mutations which lead to the expression of AML1B variants defective for DNA-binding or lacking its C-terminal domains. 170 Similar mutations have also been detected in about 5% of patients with myelodysplastic syndrome (H Hirai, personal communication). One Model indicating how CBF oncoproteins may contribute to leukemogenesis. CBF␤-SMMHC, AML1-ETO, AML1-MDS1/EVI1 and TEL-AML1 each inhibit CBF activities. As a result, cell cycle progression during G1, differentiation and p53 induction in response to environmental stress are inhibited. Second genetic mutations potentially by-pass inhibition of G1 by CBF oncoproteins. In addition, each oncoprotein has unique interactions which may also contribute to leukemogenesis. CBF␤SMMHC binds and alters the actin cytoskeleton and so may alter adhesion. ETO binds the related MTGR1 via NHR2. The Runt domain of AML1-ETO, and likely AML1-MDS1/EVI1 and TEL-AML1 as well, binds C/EBP␣ and several Ets factors. These interactions could interfere with the activities of C/EBP␣ or PU.1. EVI1 binds Smad3 and inteferes with TGF␤ signalling. TEL-AML1 binds TEL and Fli-1 via its PNT domain and thereby likely interferes with their activities (see text for further discussion and citations).
consequence of CBF inhibition is likely to be inhibition of myeloid differentiation. However, reduced CBF activity also slows cell cycle progression during G1, at least in cell lines. Mutations which accelerate G1 are common in malignant cells. For example, the p15 and p16 promoters are often inactivated by methylation in AML at diagnosis, and these genes are deleted in 20% of pediatric B-lineage ALL. [171] [172] [173] Also, the p27 gene is located near the TEL gene, and one copy is often deleted with a TEL allele in ALL. 174 The presence of such second genetic 'hits' in CBF leukemias may enable increased activity of CBF oncoproteins, potentiating their ability to inhibit differentiation. However, additional genetic alterations consistently present in CBF leukemias remain to be elucidated.
The CBF oncoproteins themselves might facilitate the development of additional mutations and/or stimulate cell survival by inhibiting p53 induction in response to DNA-damage or hypoxia. 93 In normal cells, p53 induction activates cell cycle checkpoints, leading to growth arrest and DNA repair or apoptosis. 175, 176 p53 mutations, although common in malignancies, are rare in de novo AML. 177 Like AML1-ETO, PML-RAR␣ and PLZF-RAR␣, oncoproteins associated with FAB M3 AML, interact with complexes containing histone deacetylases. 101, 102, 178 These observations have led to the suggestion that interaction with this corepressor complex results in a common mechanism of leukemogenesis by CBF oncoproteins and the RAR␣ fusion oncoproteins. 101, 102 Since CBF and RAR␣ have not been shown to regulate a common set of genes, I believe that this idea remains speculative, although the possibility that histonedeacetylase inhibitors may be useful for the therapy of both CBF leukemias and M3 AML is worthy of clinical evaluation.
If inhibition of differentiation is central to leukemogenesis by CBF oncoproteins, why do M2 AMLs carrying t(8;21) express high levels of MPO and retain the ability to differentiate to neutrophils in vitro in response to G-CSF? 179 Two possible answers to this question can be considered. First, inhibition of granulopoiesis by AML1-ETO may occur at a stage subsequent to activation of the MPO gene. Second, inhibition of differentiation may occur in an immature progenitor, with this effect being leaky. Consistent with the second possibility is the observation that only a very small percent of AML cells retain the ability to repopulate an immune-deficient mouse. 180 Two observations raise the possibility that increased CBF activities contribute to transformation in CBF leukemias. CBF␣1, when over-expressed in mice as a result of retroviral insertion, can cooperate with c-myc to transform T cells. 181 Also, infants with Down syndrome carry an extra copy of the AML1 gene on chromosome 21. Perhaps this accounts for their propensity to develop transient myeloproliferative syndrome and acute myeloid and lymphocytic leukemia. Thus, while CBF oncoproteins are clearly capable of inhibiting CBF, it remains possible that their activation of a key gene is important for leukemogenesis.
As indicated in Figure 2 , each of the AML1 or CBF␤ partners have the potential to contribute to leukemogenesis via unique interactions with other proteins or with DNA. The AML1 Runt domain may engage in protein-protein interactions relevant to transformation as well. For example, interactions between AML1-ETO and C/EBP␣ or PU.1 could theoretically lead to reduced activity of C/EBP␣-or PU.1-regulated genes. 30, 87 AML1-ETO was in fact recently shown to inhibit transcription by tethering to DNA via MEF, another Ets factor.
182 AML1-ETO and AML1 interact with MEF via the C-terminal portion of the Runt domain. The contributions of the AML1, SMMHC, ETO, MDS1/EVI1 and TEL domains likely account in part for phenotypic differences between the subsets of acute leukemia which express CBF oncoproteins.
Apoptosis of CBF leukemias
Patients with AML associated with inv(16) or t(8;21) have approximately a 60% chance of remaining in long-term complete remission (CR), compared with a 30% CR rate for the balance of AML patients. 183, 184 Pediatric patients with Blineage ALL and t(12;21) have approximately 95% chance for achieving long-term CR, compared with 70% for the remainder. 164, 185 What accounts for the improved prognosis of the majority of patients with a CBF leukemia? AML patients receiving highdose cytarabine (400 or 3000 mg/m 2 /day) during consolidation therapy did three times as well as those receiving only 100 mg/m 2 /day. 184 Cytarabine is a deoxycytidine analog which becomes phosphorylated intracellularly, gets incorporated into DNA during S phase, and disrupts S phase progression. The mainstays of pediatric B-lineage ALL therapy are methotrexate and 6-mercaptopurine. Methotrexate inhibits thymidine production and so DNA synthesis, and 6-mercaptopurine is converted into a ribonucleotide which can also interfere with DNA synthesis. Perhaps S-phase agents such as these induce a pathway leading to apoptosis which is more active in leukemic cells having reduced CBF activity. Consistent with this model, AMLs carrying inv(16) or t(8;21) undergo cell death more rapidly than other AMLs when placed in serumfree media. 186 Alternatively, inhibition of CBF might favorably alter the intracellular metabolism of these chemotherapy drugs. Paradoxically, CBF␤-SMMHC slowed apoptosis of Ba/F3 cells exposed to etoposide or ionizing radiation. 93 However, Ba/F3 lines expressing CBF␤-SMMHC underwent apoptosis more rapidly than Ba/F3 cells expressing bcr-abl (p210), paralleling the increased responsiveness of CBF leukemias relative to other leukemias.
Defining the molecular pathways underlying leukemogenesis by CBF oncoproteins and heightened chemotherapy sensitivity in CBF leukemias is likely to lead to improved therapies for these and other subsets of acute leukemia.
Perspective and future directions
CBF is a key regulator of early hematopoiesis, and its subunits are involved in several translocations associated with acute leukemias. Identifying the direct genetic targets of the CBF oncoproteins, using techniques such as representational difference analysis and DNA microarray screening, will likely provide important insights into their mechanisms of leukemogenesis. Choosing the proper system for applying these methods is, however, difficult. When expressed in isolation, in mice or in cell lines, CBF␤-SMMHC or AML1-ETO inhibit cell accumulation, underscoring the need for additional genetic changes to enable leukemogenesis. In the presence of these additional genetic changes, the profile of genes affected by CBF oncoproteins may change. Therefore, systems in which the expression of a CBF oncoprotein is inhibited in a primary human leukemia or in which a CBF oncoprotein is coexpressed with appropriate additional genetic alterations would be ideal.
Identifying genetic changes consistently present in CBF leukemias will assist the development of appropriate animal models for identifying CBF oncoprotein genetic targets and will provide insight into the process of transformation in CBF leukemias. Such analysis could be undertaken using DNA and RNA isolated from primary leukemias. In addition, the ability to expand CBF and other leukemias in NOD/SCID immunedeficient mice promises to provide a rich source of experimental material for the biochemical characterization of their cell cycle, apoptosis and differentiation pathways. Differences observed between therapy-responsive and non-responsive CBF leukemias will provide important clues for the development of novel biologic therapies.
The ability of retinoic acid to overcome PML-RAR␣-mediated transcriptional repression, enabling the differentiation of M3 AMLs harboring t (15;17) , raises the hope that agents which prevent CBF oncoproteins from interfering with endogenous CBF would also stimulate leukemic differentiation or apoptosis and contribute to the therapy of patients with CBF leukemias. Perhaps small molecules which interfere with the multimerization of CBF␤-SMMHC or with interaction of AML1-ETO with co-repressor complexes can be identified and evaluated in the clinical setting.
